Drug intelligence / Profile preview

tramadol hydrochloride + gamma-aminobutyric acid

Development stage
Unknown
Lead developer
Physician Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

**Tramadol hydrochloride + gamma-aminobutyric acid** is a small-molecule combination corresponding to the analgesic opioid tramadol hydrochloride administered together with gamma-aminobutyric acid as part of a proprietary amino-acid blend in the Theramine medical food component of the THERATRAMADOL-90 kit distributed by Physician Therapeutics. In the cited context, the combination is positioned for the dietary management of pain and inflammation rather than as an FDA-approved fixed-dose pharmaceutical product. Mechanistically, tramadol is a centrally acting analgesic with opioid receptor agonist activity and inhibition of monoamine reuptake, while gamma-aminobutyric acid is included as a nutritional or nutraceutical component rather than a well-defined approved analgesic active ingredient in this specific product configuration.

Other names
tramadol hydrochloride + gamma-aminobutyric acid
02

Targets

GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on tramadol hydrochloride + gamma-aminobutyric acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tramadol hydrochloride + gamma-aminobutyric acid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call